-+ 0.00%
-+ 0.00%
-+ 0.00%

10x Genomics Collaborates With Dana-Farber Cancer Institute To Analyze Tumor Samples From Patients With Major Solid Cancer Types To Uncover Biological Features Related To Treatment Response, Resistance And Disease Progression; Co. Plans To Establish CLIA-Certified Laboratory

Benzinga·01/12/2026 14:20:44
Listen to the news

Collaboration with Dana-Farber Cancer Institute aims to identify biomarkers linked to treatment response for the next generation of cancer therapies and to define a clinical reporting framework to power precision oncology

10x also plans to establish a CLIA-certified laboratory to enable development of future innovative diagnostic tests

PLEASANTON, Calif., Jan. 12, 2026 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today announced a collaboration with Dana-Farber Cancer Institute to analyze tumor samples from patients with major solid cancer types to uncover biological features associated with treatment response, resistance and disease progression. The company also announced plans to establish a CLIA-certified laboratory. Together, these efforts mark the beginning of a multi-year research initiative to incorporate single cell and spatial tumor analysis into potential diagnostic workflows to support cancer patient care.